Blood thinners may cut death in Covid patients

eAwaz Medicine

Toronto – A study, led by investigators at St Michael’s Hospital in Canada, shows administering a full dose of a standard blood thinner early to moderately ill hospitalised patients with Covid-19 could halt the formation of blood clots and reduce the risk of severe disease and death. These investigators and the University of Vermont in the US, showed that heparin — a blood thinner given regularly at low dose to hospitalised patients — stops clots from forming and reduces inflammation. Mary Cushman, Professor of medicine from Vermont’s Larner College of Medicine, said: “This study was designed to detect a difference in the primary outcome that included ICU transfer, mechanical ventilation or death.” First author Michelle Sholzberg, Head of Division of Hematology-Oncology, at St. Michael’s Hospital of Unity Health Toronto, and assistant professor at the University of Toronto, said: “While we found that therapeutic heparin didn’t statistically significantly lower incidence of the primary composite of death, mechanical ventilation or ICU admission compared with low dose heparin, the odds of all-cause death were significantly reduced by 78 per cent with therapeutic heparin. We believe that the findings of our trial and the multiplatform trial taken together should result in a change in clinical practice for moderately ill ward patients with Covid-19.”